Stem cell secrets allow researchers to revamp reprogramming

Stem cell secrets allow researchers to revamp reprogramming

Stem cell secrets allow researchers to revamp reprogramming

Key points:

  • Researchers have identified key factors that promote the reprogramming of human stem cells to the naïve state, which can be used to model the earliest stages of development.
  • This new knowledge will help researchers to generate naïve pluripotent stem cells more efficiently and quickly.
  • Their study also provides details of the molecular events that take place in cell state transitions.
  • Their findings also provide new insights into the mechanisms that destabilise and reconfigure cell identity during cell state transitions.

Researchers from the Babraham Institute’s Epigenetics research programme have been able to learn more about naïve stem cell reprogramming following a genome wide functional screen. Their research, published today in Science Advances, describes the critical regulators of reprogramming and offers opportunities for a more efficient, faster way to generate human naïve pluripotent stem cells.

Human pluripotent stem cells (PSCs) are a useful tool for researchers investigating how cells specialise to make every tissue of our body. They come in two different states, primed and naïve. Both types of PSC can self-renew and differentiate into new cell types but they have distinct functions and molecular characteristics.

Group leader Dr Peter Rugg-Gunn explained the importance of these cells: “Human PSCs in the naïve state replicate the key molecular and cellular characteristics of cells in a pre-implantation stage embryo. Importantly, when naïve PSCs are encouraged to self-organise in particular conditions, they form structures that resemble an early blastocyst stage of development. By growing these cells in the lab, we can learn about the key events that happen during human development, and they have potential uses in personalised medicine. But we need to create high-quality, stable stem cell populations to be able to conduct our experiments.”

Pluripotent stem cells are formed either from embryos or using Nobel Prize-winning methods to remove cell identity from specialised cells. The majority of reprogramming experiments generate primed PSCs, which are more developmentally advanced than naïve PSCs.  Naïve PSCs can be collected directly from human pre-implantation embryos, or more commonly researchers expose primed PSCs to conditions that induces them to become naïve PSCs. Existing methods for reprogramming were inefficient and slow, preventing researchers from quickly producing the numbers of high-quality stem cells they needed.

Adam Bendall, PhD student and a lead researcher on the study, said: “Very little was known about what genetic and epigenetic factors are required for naïve cell reprogramming, and this knowledge gap limited the design of reprogramming conditions.”

The low efficiency of naïve reprogramming suggests the presence of barriers that limit cells in reaching the naïve state. Adam and his colleagues honed in on these barriers by performing a large-scale genetic screen to identify genes that hinder and help reprogramming. They were able to identify a large number of genes that have a crucial role in naïve PSC programming that had not been previously linked to the process.

The team focused on one epigenetic complex in particular, the PRC1.3 complex, that regulates gene expression without altering the underlying DNA sequence, and which they found to be essential for the formation of naïve PSCs. Without this complex, the cells undergoing reprogramming become a completely different type of cell rather than naïve PSCs. This suggests that the activity of PRC1.3 could encourage more cells to reprogramme properly, in effect lowering the barrier.

After identifying factors that promote reprogramming, the researchers also looked at factors that impede reprogramming, exemplified in their study by an epigenetic protein called HDAC2. Dr Amanda Collier, first author on the paper, explained: “Excitingly, when we inhibited one of these factors using selective chemicals, then naïve PSC reprogramming occurred more efficiently and rapidly. We’re able to look at it from both sides; we can remove the barriers and introduce the factors that push cells towards state change.”

Not only does this research improve scientists’ ability to produce human naïve PSCs, it provides details on the molecular events that occur during the cell state transition itself, some of which are conserved in developmental regulation in human embryos.

The Rugg-Gunn lab are putting together the pieces of a bigger puzzle - the best understanding of the formation and control of naïve stem cells. Their previous research has identified molecular factors that help to maintain cells in a naïve stage. Group leader, Dr Peter Rugg-Gunn said: “By building up our tools for manipulating pluripotent stem cells, we can spend more time asking important questions about the pre-implantation embryo. In the longer term, further improvements in working with naïve PSCs might open up the possibility for using these cells in personalised disease models or cell therapies, although this will require more research on how to differentiate naïve PSCs into specialised cell types.”

Notes to Editors

Publication reference

Collier et al.,

Genome-Wide Screening Identifies Polycomb Repressive Complex 1.3 as an Essential Regulator of Human Naïve Pluripotent Cell Reprogramming

Science Advances, 2022

Press contact:

Honor Pollard, Communications Officer,

Image description:

Immunofluorescent microscopy images show the different morphology of reprogrammed pluripotent stem cells (orange) and cells that were not reprogrammed (purple).

Affiliated authors (in author order):

Amanda Collier, former PhD student, Rugg-Gunn lab

Adam Bendall, PhD student, Rugg-Gunn lab

Charlene Fabian, former PhD student, Rugg-Gunn lab

Andrew Malcolm, PhD student, Rugg-Gunn lab

Claudia Semprich, postdoctoral researcher, Rugg-Gunn lab

Katarzyna Wojdyla, former postdoctoral researcher, Rugg-Gunn lab

Paola Nisi, former visiting PhD student, Rugg-Gunn lab

Peter Rugg-Gunn, Group leader, Epigenetics research programme

Research funding

This research was funded by the BBSRC, the Medical Research Council and the Wellcome Trust.

Additional/related resources:

Rugg-Gunn lab page

News 1 September 2021, The key to staying naïve

About the Babraham Institute

The Babraham Institute undertakes world-class life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research focuses on cellular signalling, gene regulation and the impact of epigenetic regulation at different stages of life. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and support healthier ageing. The Institute is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, through Institute Strategic Programme Grants and an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities.


The Biotechnology and Biological Sciences Research Council (BBSRC) is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.

Funded by government, BBSRC invested £451 million in world-class bioscience in 2019-20. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.